MedPath

Prednisolone only and a combination of prednisolone and mizoribine for primary nephrotic syndrome relapsed within six mounths after first onset in children: A randomized controlled trial of efficacy and safety (JSRDC06)

Not Applicable
Conditions
Steroid-sensitive nephrotic syndrome
Registration Number
JPRN-C000000379
Lead Sponsor
Japanese Study Group of Renal Disease in Children(JSRDC)
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

1.History of relapse. 2.Medical history of allergy or hypersensitivity reactions to mizoribine. 3.Poorly controlled hypertension. 4.Chronic renal dysfunction. 5.Active infectious disease. 6.Severe liver disfunction. 7.History of saireito and immunosupression administration. 8.Pregnancy. 9.Judged inappropriate for this study by the physicians.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Relapse-free period
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath